Cybin Unveils Record Q1 Financials and Key Milestones
Cybin Inc., a clinical-stage neuropsychiatry company, reported its financial results for the first quarter ended June 30, 2024, and...
Merck Unveils Groundbreaking ESCC Trial Results: Unlocking New Hope for Patients
Merck has announced the termination of the KeyVibe-008 Phase 3 trial evaluating the combination of vibostolimab and pembrolizumab in...
Neurogene’s Triumphant Progress in NGN-401 Gene Therapy
Neurogene Inc. has made significant progress in its clinical-stage development of NGN-401 gene therapy for Rett syndrome. The therapy...
Merck to Secure Novel B-Cell Therapy CN201 in Deal with Curon Bio
Merck (MSD outside the US and Canada) has acquired CN201, a novel bispecific antibody, from Curon Biopharmaceutical. CN201 targets...
C2N Diagnostics and Unilabs Forge Unprecedented Alliance to Advance Brain Health
In a groundbreaking partnership, Unilabs and C2N Diagnostics are collaborating to enhance brain health diagnostics and research in Europe...
US Oncology Network Grows in Tennessee with New Partnership
Tennessee Cancer Specialists (TCS), the largest community-based oncology practice in eastern Tennessee and the third largest statewide, has joined...
Neurogene’s NG-401 Gets RMAT Designation for Rett Syndrome Treatment
Neurogene’s NGN-401, a gene therapy, has obtained Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating Rett...
eClinical Solutions’ Protocol Deviations Boost Clinical Trial Success
eClinical Solutions has introduced enhancements and AI-powered functionalities to its Elluminate Clinical Data Cloud platform. These updates aim to...
Sangamo Inks Capsid Delivery Deal With Genetech for Neurodegenerative Diseases
Sangamo Therapeutics and Genentech, a Roche Group member, have joined forces to develop intravenous genomic treatments for neurodegenerative diseases....
Artera Announces Prostate Test Expansion in Prostate Cancer Patients
Artera has improved its ArteraAI Prostate Test to support clinicians in determining the suitability of active surveillance for prostate...